XML 185 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure [Table]      
Pay vs Performance [Table Text Block]

Pay Versus Performance

In accordance with rules adopted by the SEC pursuant to the Dodd-Frank Act, we provide the following disclosure regarding executive compensation for our principal executive officer (“PEO”) and Non-PEO NEOs and Company performance for the fiscal years listed below. The Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown.

                                 
                  Average
Summary		    Average    Value of Initial
Fixed $100 Investment
based on:(4)    		          
Year  Summary
Compensation
Table Total for
Mr. Bienaimé(1)
($)		  Compensation
Actually Paid to
Mr. Bienaimé
(1),(2),(3)
($)		  Compensation
Table Total for
Non-PEO
NEOs(1)
($)		  Compensation
Actually Paid to
Non-PEO
NEOs(1),(2),(3)
($)		  TSR
($)		     Peer
Group
TSR
($)		  GAAP Net
Income
(Loss)
($ Millions)		  Managed
Sales
Revenue
($ in
Millions)(5)
2022  18,351,880  34,379,532  6,114,555  10,821,939  122.40  113.65  141.6  1,914
2021  18,262,538  18,390,254  5,510,297  5,670,256  104.49  126.45  (64.1)  1,655
2020  18,146,399  22,341,893  5,195,953  4,752,027  103.71  126.42  854.0  1,664
    
Company Selected Measure Name Managed Sales Revenue    
Named Executive Officers, Footnote [Text Block]
(1) Jean-Jacques Bienaimé was our PEO for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below.

  2020   2021   2022
  Brian R. Mueller   Brian R. Mueller   Brian R. Mueller
  Jeff Ajer   Jeff Ajer   Jeff Ajer
  Henry J. Fuchs, M.D.   Henry J. Fuchs, M.D.   Henry J. Fuchs, M.D.
  C. Greg Guyer, Ph.D.   C. Greg Guyer, Ph.D.   G. Eric Davis
  Robert A. Baffi, Ph.D.        
  Daniel Spiegelman        
    
Peer Group Issuers, Footnote [Text Block] The Peer Group TSR set forth in this table utilizes the Nasdaq Biotechnology Index (“Nasdaq Biotech Index”), which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report on Form 10-K for the year ended December 31, 2022. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Nasdaq Biotech Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.    
PEO Total Compensation Amount $ 18,351,880 $ 18,262,538 $ 18,146,399
PEO Actually Paid Compensation Amount $ 34,379,532 18,390,254 22,341,893
Adjustment To PEO Compensation, Footnote [Text Block]
(3) Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.
                   
  Year     Summary Compensation
Table Total for
Mr. Bienaimé
($)		      Exclusion of Stock Awards
and Option Awards for
Mr. Bienaimé
($)		      Inclusion of Equity Values for
Mr. Bienaimé
($)		      Compensation Actually Paid to
Mr. Bienaimé
($)
  2022   18,351,880   (14,829,402)   30,857,054   34,379,532
  2021   18,262,538   (14,589,346)   14,717,062   18,390,254
  2020   18,146,399   (15,061,322)   19,256,816   22,341,893

The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:

                               
  Year    Year-End Fair
Value of
Equity Awards
Granted During
Year That
Remained
Unvested as of
Last Day of
Year for
Mr. Bienaimé
($)		    Change in
Fair Value
from Last
Day of Prior
Year to Last
Day of Year
of Unvested
Equity Awards for
Mr. Bienaimé
($)		    Vesting-Date
Fair Value of
Equity Awards
Granted During
Year that
Vested During
Year for
Mr. Bienaimé
($)		    Change in Fair
Value from
Last Day of
Prior Year to
Vesting Date of
Unvested Equity
Awards that
Vested During
Year for
Mr. Bienaimé
($)		    Fair Value at
Last Day of
Prior Year of
Equity Awards
Forfeited During
Year for
Mr. Bienaimé
($)		    Value of
Dividends or
Other Earnings
Paid on Stock or
Option Awards
Not Otherwise
Included for
Mr. Bienaimé
($)		    Total - Inclusion of
Equity Values for
Mr. Bienaimé
($)
  2022  19,531,007  12,607,769  —  (1,281,722)  —  —  30,857,054
  2021  16,269,126  173,631  —  (1,725,695)  —  —  14,717,062
  2020  19,065,108  578,838  —  (387,130)  —  —  19,256,816
    
Non-PEO NEO Average Total Compensation Amount $ 6,114,555 5,510,297 5,195,953
Non-PEO NEO Average Compensation Actually Paid Amount $ 10,821,939 5,670,256 4,752,027
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]
(3) Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option Awards columns set forth in the Summary Compensation Table.
                   
  Year    Average Summary
Compensation Table
Total for Non-PEO NEOs
($)		    Average Exclusion
of Stock Awards and
Option Awards for
Non-PEO NEOs
($)		    Average Inclusion of
Equity Values for
Non-PEO NEOs
($)		    Average Compensation
Actually Paid to
Non-PEO NEOs
($)
  2022  6,114,555  (4,852,702)  9,560,086  10,821,939
  2021  5,510,297  (4,107,977)  4,267,936  5,670,256
  2020  5,195,953  (3,885,645)  3,441,719  4,752,027

The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:

                               
  Year    Average
Year-End
Fair Value of
Equity Awards
Granted During
Year That
Remained Unvested
as of Last Day
of Year for
Non-PEO NEOs
($)		    Average
Change in
Fair Value from
Last Day of
Prior Year to
Last Day of
Year of
Unvested Equity
Awards for
Non-PEO NEOs
($)		    Average
Vesting-Date
Fair Value of
Equity Awards
Granted During
Year that
Vested During
Year for
Non-PEO NEOs
($)		    Average
Change in
Fair Value
from Last Day
of Prior Year to
Vesting Date of
Unvested
Equity Awards
that Vested
During Year for
Non-PEO NEOs
($)		    Average
Fair Value
at Last Day of
Prior Year of
Equity Awards
Forfeited During
Year for
Non-PEO NEOs
($)		    Average
Value of
Dividends or
Other Earnings
Paid on
Stock or Option
Awards Not
Otherwise
Included for
Non-PEO NEOs
($)		    Total – Average
Inclusion of
Equity Values for
Non-PEO NEOs
($)
  2022  6,541,104  3,376,323  —  (357,341)  —  —  9,560,086
  2021  4,580,949  73,649  —  (386,662)  —  —  4,267,936
  2020  4,289,689  109,067  —  (79,431)  (877,606)  —  3,441,719
    
Compensation Actually Paid vs. Total Shareholder Return [Text Block]

Description of Relationship Between Compensation Actually Paid and Company Total Shareholder Return (“TSR”)

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and the Company’s cumulative TSR over the three most recently completed fiscal years.

PEO AND AVERAGE NEO COMPENSATION ACTUALLY PAID VERSUS BIOMARIN TSR

    
Compensation Actually Paid vs. Net Income [Text Block]

Description of Relationship Between Compensation Actually Paid and GAAP Net Income (Loss)

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our GAAP Net Income (Loss) during the three most recently completed fiscal years.

PEO AND AVERAGE NEO COMPENSATION ACTUALLY PAID VERSUS BIOMARIN GAAP NET INCOME (LOSS)

    
Compensation Actually Paid vs. Company Selected Measure [Text Block]

Description of Relationship Between Compensation Actually Paid and Managed Sales Revenue ($ in Millions)

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our other NEOs, and our Managed Sales Revenue ($ in Millions) during the three most recently completed fiscal years.

PEO AND AVERAGE NEO COMPENSATION ACTUALLY PAID VERSUS BIOMARIN MANAGED SALES REVENUE ($ IN MILLIONS)

    
Total Shareholder Return Vs Peer Group [Text Block]

Description of Relationship Between Company TSR and Peer Group TSR

The following chart compares our cumulative TSR over the three most recently completed fiscal years to that of the Nasdaq Biotechnology Index over the same period.

COMPARISON OF CUMULATIVE TSR OF BIOMARIN AND NASDAQ BIOTECHNOLOGY INDEX

    
Tabular List [Table Text Block]

Tabular List of Most Important Financial and Non-Financial Performance Measures

The following table presents the financial and non-financial performance measures the Company considers to have been the most important in linking Compensation Actually Paid to our PEO and other NEOs for 2022 to Company performance. The measures in this table are not ranked.

 
Managed Sales Revenue
Core Operating Margin
Relative TSR
Non-GAAP Income
Number of Product Regulatory Approvals by the FDA and EMA and IND/CTAs submitted to the FDA and EMA
Number of Development Programs that Achieve Proofs of Concept or Meet Clinical Milestones

All information provided above under the “Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference.

    
Total Shareholder Return Amount $ 122.40 104.49 103.71
Peer Group Total Shareholder Return Amount 113.65 126.45 126.42
Net Income (Loss) Attributable to Parent $ 141,600,000 $ (64,100,000) $ 854,000,000.0
Company Selected Measure Amount 1,914,000,000 1,655,000,000 1,664,000,000
PEO Name Jean-Jacques Bienaimé Jean-Jacques Bienaimé Jean-Jacques Bienaimé
Measure [Axis]: 1      
Pay vs Performance Disclosure [Table]      
Measure Name Managed Sales Revenue    
Non-GAAP Measure Description [Text Block] We determined Managed Sales Revenue to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2022. See footnote (2) to 2022 Program Goals and Results table set forth in our CD&A on page 60 of this Proxy Statement for a description of how this performance measure is derived from our GAAP financial reporting. Managed Sales Revenue is based on total net product revenue calculated in accordance with U.S. GAAP, except that it excludes net product revenue attributable to ALDURAZYME because the product is commercialized by Sanofi under a collaboration agreement with the Company. This performance measure may not have been the most important financial performance measure for years 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years.    
Measure [Axis]: 2      
Pay vs Performance Disclosure [Table]      
Measure Name Core Operating Margin    
Measure [Axis]: 3      
Pay vs Performance Disclosure [Table]      
Measure Name Relative TSR    
Measure [Axis]: 4      
Pay vs Performance Disclosure [Table]      
Measure Name Non-GAAP Income    
Measure [Axis]: 5      
Pay vs Performance Disclosure [Table]      
Measure Name Number of Product Regulatory Approvals by the FDA and EMA and IND/CTAs submitted to the FDA and EMA    
Measure [Axis]: 6      
Pay vs Performance Disclosure [Table]      
Measure Name Number of Development Programs that Achieve Proofs of Concept or Meet Clinical Milestones    
P E O Member Exclusion Of Stock Awards And Option Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount $ (14,829,402) $ (14,589,346) $ (15,061,322)
P E O Member Inclusion Of Equity Values [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 30,857,054 14,717,062 19,256,816
Non Peo Neo Member Average Exclusion Of Stock Awards And Option Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount (4,852,702) (4,107,977) (3,885,645)
Non Peo Neo Member Average Inclusion Of Equity Values [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 9,560,086 4,267,936 3,441,719
P E O Member Year End Fair Value Of Equity Awards Granted During Year That Remained Unvested As Of Last Day Of Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 19,531,007 16,269,126 19,065,108
P E O Member Change In Fair Value From Last Day Of Prior Year To Last Day Of Year Of Unvested Equity Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 12,607,769 173,631 578,838
P E O Member Vesting Date Fair Value Of Equity Awards Granted During Year That Vested During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 0 0 0
P E O Member Change In Fair Value From Last Day Of Prior Year To Vesting Date Of Unvested Equity Awards That Vested During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount (1,281,722) (1,725,695) (387,130)
P E O Member Fair Value At Last Day Of Prior Year Of Equity Awards Forfeited During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 0 0 0
P E O Member Value Of Dividends Or Other Earnings Paid On Stock Or Option Awards Not Otherwise Included [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 0 0 0
P E O Member Total Inclusion Of Equity Values [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 30,857,054 14,717,062 19,256,816
Non P E O N E O Member Average Year End Fair Value Of Equity Awards Granted During Year That Remained Unvested As Of Last Day Of Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 6,541,104 4,580,949 4,289,689
Non P E O N E O Member Average Change In Fair Value From Last Day Of Prior Year To Last Day Of Year Of Unvested Equity Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 3,376,323 73,649 109,067
Non P E O N E O Member Average Vesting Date Fair Value Of Equity Awards Granted During Year That Vested During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 0 0 0
Non P E O N E O Member Average Change In Fair Value From Last Day Of Prior Year To Vesting Date Of Unvested Equity Awards That Vested During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount (357,341) (386,662) (79,431)
Non P E O N E O Member Average Fair Value At Last Day Of Prior Year Of Equity Awards Forfeited During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 0 0 (877,606)
Non P E O N E O Member Average Value Of Dividends Or Other Earnings Paidon Stock Or Option Awards Not Otherwise Included [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 0 0 0
Non P E O N E O Member Total Average Inclusion Of Equity Values [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount $ 9,560,086 $ 4,267,936 $ 3,441,719